Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
06/2003
06/26/2003US20030119916 Treatment of functional gastrointestinal disorders
06/26/2003US20030119903 Use of trimebutine for treating pain
06/26/2003US20030119895 Anticancer agents
06/26/2003US20030119888 Composition comprising l-arginine as a muscle growth stimulant and use thereof
06/26/2003US20030119877 Pyridine derivatives useful as cyclooxygenase inhibitor
06/26/2003US20030119868 Gyrase inhibitors and uses thereof
06/26/2003US20030119862 Pharmaceutical combination
06/26/2003US20030119860 Administering to the mammal suffering from non-rheumatoid arthritis a therapeutically effective amount of a secretory phospholiase A2 (sPLA2) inhibitors to treat rheumatoid (an indole compound)
06/26/2003US20030119859 Useful in the prophylaxis and treatment of respiratory diseases
06/26/2003US20030119847 Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1
06/26/2003US20030119837 Pharmaceutical composition for the treatment of CNS and other disorders
06/26/2003US20030119834 Angiogenesis inhibitors; 3-alkyl-4-one quinazoline derivatives
06/26/2003US20030119824 Treatment of inflammatory bowel disease
06/26/2003US20030119809 Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
06/26/2003US20030119808 Coadministration of a sterol or 5-alpha-stanol absorption inhibitor (aryl-substituted azetidines) and a HMG-CoA reductase inhibitor, the latter being used sparingly in amounts insufficient to cause muscle degeneration.
06/26/2003US20030119804 Otic microbial combination for treatment of animals with ruptured tympanic membrane
06/26/2003US20030119800 Administering an ANGELS (Activators of Non-Genotropic Estrogen-like Signaling compound"ANGELS") compound to maintain or increase bone mass, bone density and/or bone strength.
06/26/2003US20030119797 Methods for selective immunomodulation
06/26/2003US20030119796 Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
06/26/2003US20030119794 Also containing an acetylsalicylate anionand a beta-receptor blocker or a hypertensive agent; especially treating cardiac arrest, angina and shock
06/26/2003US20030119790 Substituted phenol compounds useful for anesthesia and sedation
06/26/2003US20030119788 N-cyanomethyl carbonamides and sulfonamides which are cysteine protease, particularly cathepsin K, inhibitors
06/26/2003US20030119786 Combinations for the treatment of immunoinflammatory disorders
06/26/2003US20030119784 Treating and preventing diarrhea and scours
06/26/2003US20030119776 Synthetic oligonucleotide sequence of 2 to 10 bases; treating autoimmune encephalomyelitis, cancer, and graft rejection, tissue rejection or cell rejection.
06/26/2003US20030119773 Method for enhancing an immune response
06/26/2003US20030119764 Analog is incorporated by a polymerase into an RNA copy of a genomic nucleic acid encoding the virus, and replaces a first natural occurring nucleotide having a first complementary nucleotide
06/26/2003US20030119757 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
06/26/2003US20030119755 Methods for alleviating mucositis
06/26/2003US20030119752 Inhibiting particularly the activity of hepatitis C virus NS3-NS4A protease; peptidomimetics having a bridged bicyclic moiety at the P2 position.
06/26/2003US20030119742 Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587,10183, 10550, 12680, 17921, 32248, 60489 or 93804
06/26/2003US20030119729 Promoting survival of substantia nigra neuronal cells by contacting with a trophic amount of a ptc therapeutic; mimics hedgehog-mediated patched signal transduction; treating or preventing Parkinson's Disease
06/26/2003US20030119727 FVIIa antagonists
06/26/2003US20030119726 P-glycoproteins and uses thereof
06/26/2003US20030119719 Use of endothelin conjugates in therapy, new endothelin conjugates, agents that contain the latter, and process for their production
06/26/2003US20030119718 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
06/26/2003US20030119717 Synergistic activation of regulatory elements by rel proteins and a steroid receptor
06/26/2003US20030119715 Prevent retinoid binding; antiaging agents; activation cell differentiation
06/26/2003US20030119714 Using neuropeptide y inhibitor; side effect reduction
06/26/2003US20030119684 Conditioning solution for contact lenses and a method of using the same
06/26/2003US20030119428 Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
06/26/2003US20030119184 Cells seeded hollow fibers; ultrafiltration
06/26/2003US20030119168 Diagnosis of anticancer agents using nucleic acids
06/26/2003US20030119111 G-protein coupled receptor, named 2871 receptor
06/26/2003US20030119101 Bactericides, fungicides; transporter proteins
06/26/2003US20030119072 Methods for modulating signal transduction mediated by TGF-beta related proteins
06/26/2003US20030119045 Controlling cell proliferation; adjust adhesion to substrate
06/26/2003US20030119036 Isolated nucleic acids; anticholesterol agents, cardiovascular disorders, antiinflammatory agents, antilipemic agents
06/26/2003US20030119013 Identification of essential genes of Aspergillus fumigatus and methods of use
06/26/2003US20030118990 Novel estrogen-regulated G protein gamma subunit: compositions and methods of use
06/26/2003US20030118988 Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof
06/26/2003US20030118669 Novel substituted benzimidazole dosage forms and method of using same
06/26/2003US20030118666 Injectable solution containing a shark-derived chondroitin sulfate iron colloid
06/26/2003US20030118655 Film forming liquid composition
06/26/2003US20030118648 Two combined tablet portions, with different releasing rates; drug delivery providing immediate, sustained and prolonged release
06/26/2003US20030118638 Oral pharmaceutical products containing 17 beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation
06/26/2003US20030118637 Preventing antibody-induced anemia by administering a complexes of bisphosphonate
06/26/2003US20030118633 Treating unstable or overactive urinary bladder by administering an antimuscarinic agent and an estrogen agonist
06/26/2003US20030118600 Transfer compounds, production and use thereof
06/26/2003US20030118582 Pharmaceutical composition comprising factor VII polypeptides and protein C inhibitors
06/26/2003US20030118564 Intra-tumoral administration of il-12 encoding nucleic acid molecules
06/26/2003US20030118557 Axon repair
06/26/2003US20030118546 Genetic engineering; polypeptides; antitumor agent
06/26/2003US20030118545 Methods and compositions for treating mammalian nerve tissue injuries
06/26/2003US20030118541 Controlling drug resistance; intensify therapy; increas accumulation in cell
06/26/2003US20030118539 Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
06/26/2003US20030118536 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003US20030118528 Topical delivery of codrugs
06/26/2003US20030118526 Mixture containing sunscreen agent; storage stability
06/26/2003US20030118517 Topical oral dosage forms containing bismuth compounds
06/26/2003US20030118507 Methods of using 46828, a human acyl-CoA synthetase
06/26/2003US20030117579 Medical devices having antimicrobial coatings thereon
06/26/2003DE10206257C1 Massage system for applying preparation with e.g. analgesic or heating effect to the skin, comprising active preparation reservoir, massaging device and contact surface adjusting system
06/26/2003CA2746308A1 Method for treating human papilloma virus
06/26/2003CA2471777A1 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003CA2471589A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003CA2470811A1 Protease inhibitors of the coagulation cascade isolated from dysidea sponges
06/26/2003CA2470624A1 Selective dopamine d3 receptor agonists for the treatment of sexual dysfunction
06/26/2003CA2470616A1 Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
06/26/2003CA2470567A1 Methods and compositions for treatment of central nervous system disorders
06/26/2003CA2470491A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003CA2470431A1 Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia
06/26/2003CA2470322A1 Methods for particle-assisted polynucleotide immunization using a pulsed electric field
06/26/2003CA2470315A1 Methods of detecting modification of genetic material
06/26/2003CA2470311A1 Method of screening compounds
06/26/2003CA2470236A1 Lactams as tachykinin antagonists
06/26/2003CA2470210A1 Use of selective pde5 inhibitors for treating partial and global respiratory failure
06/26/2003CA2470204A1 Use of dsrnas in strategic therapeutic intervention of highly active antiretroviral therapy
06/26/2003CA2469879A1 A novel sordarin derivative isolated from culture fermentations and functions as an antifungal agent
06/26/2003CA2469790A1 Method for treating circadian rhythm disruptions
06/26/2003CA2469663A1 Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
06/26/2003CA2469302A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003CA2469205A1 Bioadhesive drug delivery system with enhanced gastric retention
06/26/2003CA2468790A1 Chemokine mutants acting as chemokine antagonists
06/26/2003CA2468687A1 Liquid bisphosphonate formulations for bone disorders
06/26/2003CA2468413A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003CA2465888A1 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003CA2460806A1 Taojiks as modifiers of the beta-catenin pathway and methods of use
06/26/2003CA2453417A1 Nanoparticle delivery vehicle
06/26/2003CA2446292A1 Nucleic acid-associated proteins
1 ... 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 ... 1151